Skip to Main Content

Paper Details

Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity.
Diabetes
7
2022
GSK, GSK-, GSK-LSD1, LSD1, NAFLD, Obesity, adipocyte, chromatin, hepatocyte, hyperglycemia, insulin, lysine, lysine-specific demethylase, mice, mouse, nonalcoholic fatty liver disease, obese, obesity, type 2 diabetes
Author NameAffiliation
Philip L S M GordtsUniversity of California
Philip L S M GordtsUniversity of California
Matthew WorthamPediatric Diabetes Research Center, University of California
Maike SanderPediatric Diabetes Research Center, University of California
  • 1 - 4

Datasets

Release 1.2